• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依洛尤单抗治疗伴有实体器官移植的囊性纤维化患者的疗效。

Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.

机构信息

Department of Infectious Diseases, Cystic Fibrosis Clinic, Aarhus University Hospital, Aarhus, Denmark.

Department of Cardiology, Section for Lung Transplantation, University Hospital Rigshospitalet Copenhagen, Kobenhavn, Denmark.

出版信息

Pediatr Pulmonol. 2023 Feb;58(2):602-605. doi: 10.1002/ppul.26217. Epub 2022 Nov 11.

DOI:10.1002/ppul.26217
PMID:36314653
Abstract

We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.

摘要

我们报告了四例囊性纤维化 (CF) 患者的病例系列，这些患者在接受 elexacaftor/tezacaftor/ivacaftor 治疗 6 个月或更长时间之前曾接受过实体器官移植 (SOT)。数据是回顾性收集的。该治疗耐受性良好，所有患者均报告主观改善。

相似文献

1
Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.依洛尤单抗治疗伴有实体器官移植的囊性纤维化患者的疗效。
Pediatr Pulmonol. 2023 Feb;58(2):602-605. doi: 10.1002/ppul.26217. Epub 2022 Nov 11.
2
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
3
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
4
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
5
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
6
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
7
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-659-泰泽卡托维伐替卡与依伐卡托维在携带一个或两个 Phe508del 等位基因的囊性纤维化患者中的疗效。
N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.
8
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.一项 3 期、双盲、平行分组研究，旨在评估 tezacaftor 联合 ivacaftor 在 6 至 11 岁囊性纤维化纯合子 F508del 或杂合子 F508del-CFTR 突变和残余功能突变的参与者中的疗效和安全性。
J Cyst Fibros. 2021 Jan;20(1):68-77. doi: 10.1016/j.jcf.2020.07.023. Epub 2020 Sep 21.
9
Elexacaftor/Ivacaftor/Tezacaftor: First Approval.依伐卡托/埃乐卡福特/泰泽卡福特：首次批准。
Drugs. 2019 Dec;79(18):2001-2007. doi: 10.1007/s40265-019-01233-7.
10
Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.依库珠单抗/特扎卡托/依伐卡托治疗囊性纤维化患者的药物性痤疮。
J Cyst Fibros. 2022 Nov;21(6):1066-1069. doi: 10.1016/j.jcf.2022.09.002. Epub 2022 Sep 8.

引用本文的文献

1
The ageing of people living with cystic fibrosis: what to expect now?囊性纤维化患者的老龄化：现在有哪些预期？
Eur Respir Rev. 2024 Oct 30;33(174). doi: 10.1183/16000617.0071-2024. Print 2024 Oct.
2
Elexacaftor-tezacaftor-ivacaftor use after solid organ transplant.实体器官移植后使用依列卡福托-替扎卡福托-依伐卡托。
Curr Opin Pulm Med. 2024 Nov 1;30(6):660-666. doi: 10.1097/MCP.0000000000001110. Epub 2024 Jul 31.
3
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients.
基于生理的药代动力学模型在预测肺移植受者中依列卡福/替扎卡福/依伐卡福与他克莫司之间药物相互作用的应用。
Pharmaceutics. 2023 May 8;15(5):1438. doi: 10.3390/pharmaceutics15051438.
4
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.依列卡福妥-替扎卡福妥-依伐卡托：用于囊性纤维化的改变人生的三联组合CFTR调节剂药物。
Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410.